Ipamorelin

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a selective growth hormone secretagogue by agonizing the ghrelin/GHS receptor (GHSR). Developed by Novo Nordisk in the late 1990s, it distinguishes itself from other GH secretagogues (like GHRP-6, GHRP-2, and hexarelin) through its remarkable selectivity for GH release without significantly affecting cortisol, ACTH, prolactin, or aldosterone levels [1].

The selectivity of ipamorelin arises from its receptor binding profile. While all GHRPs activate the GHS receptor on pituitary somatotrophs to trigger GH release, most also cross-react with receptors that stimulate cortisol (via ACTH release) and prolactin. Ipamorelin binds the GHS receptor with sufficient selectivity that, even at doses 10-fold above the effective range, it does not produce meaningful elevations in these off-target hormones. This makes it the cleanest GH secretagogue available for research applications where GH-specific effects are desired without adrenal or prolactin confounders.

In preclinical and clinical studies, ipamorelin produces dose-dependent GH release with an onset of approximately 15 minutes, peak at 30–45 minutes, and return to baseline within 2–3 hours. The GH pulse amplitude is comparable to GHRP-6 but without the intense hunger response caused by ghrelin receptor activation in hypothalamic appetite centers [2]. This reduced appetite stimulation is another advantage for research protocols where caloric intake control is important.

Mechanism of Action

Ipamorelin stimulates GH release through a distinct mechanism from GHRH analogs like CJC-1295:

Ghrelin Receptor (GHS-R1a) Activation

Ipamorelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a) on pituitary somatotroph cells. This triggers intracellular calcium mobilization through the phospholipase C/inositol triphosphate (PLC/IP3) pathway, leading to GH vesicle exocytosis. The mechanism is distinct from and complementary to GHRH receptor signaling, which operates through the cAMP pathway [1].

Selectivity Profile

What makes ipamorelin unique among GHRPs is its selectivity. GHRP-6, GHRP-2, and hexarelin all stimulate significant cortisol and prolactin release at therapeutic doses. Ipamorelin, even at doses 10x above the ED50, does not produce clinically meaningful elevations in ACTH, cortisol, prolactin, or aldosterone. This selectivity was confirmed in both animal models and human pharmacodynamic studies [1].

Pulsatile GH Release Pattern

Each ipamorelin injection produces a discrete GH pulse: onset at ~15 minutes, peak at 30–45 minutes, and return to baseline by 2–3 hours. This pulsatile pattern mimics the natural physiological rhythm of GH secretion, which is considered important for maintaining receptor sensitivity and avoiding the metabolic complications associated with continuous GH exposure [2].

Bone Growth Stimulation

Research has demonstrated that ipamorelin stimulates longitudinal bone growth in rats through GH-dependent mechanisms. This effect was dose-dependent and comparable to exogenous GH administration, supporting ipamorelin's role as a physiological GH stimulant rather than a pharmacological GH analog [4].

Dosing Protocol

Ipamorelin is typically dosed multiple times daily to capitalize on pulsatile GH release. Timing relative to food intake is critical.

Reconstitution Guide

Reconstitute lyophilized ipamorelin with bacteriostatic water. The peptide dissolves readily without excessive mixing.

1. Remove the plastic cap from the ipamorelin vial and wipe the rubber stopper with an alcohol swab. Allow to dry.
2. Draw 2 mL of bacteriostatic water into a sterile syringe. For a 5 mg vial, this yields a concentration of 2,500 mcg/mL.
3. Insert the needle through the rubber stopper at a slight angle. Inject the water slowly against the inner wall of the vial — do not spray directly onto the peptide powder.
4. Allow the vial to sit for 1–2 minutes. Gently roll the vial between your palms if needed. Do not shake or vortex.
5. The solution should be completely clear and colorless. Discard if you observe any cloudiness, particulate matter, or discoloration.

Injection Technique

Ipamorelin is administered via subcutaneous (SubQ) injection. The injection site does not affect efficacy.

1. Clean the injection site with an alcohol swab and allow it to air dry completely (approximately 30 seconds). Common sites: lower abdomen (2 inches from the navel), upper thigh, or upper arm.
2. Draw the dose. Insert the needle into the vial through the rubber stopper. Invert the vial and draw the calculated number of units slowly. Tap the syringe to move any air bubbles to the top, then push them out gently.
3. Pinch the skin at the injection site to create a fold of subcutaneous tissue. Insert the needle at a 45-degree angle in a quick, smooth motion. Release the skin fold.
4. Inject slowly. Depress the plunger steadily over 5–10 seconds. Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a clean swab if needed.

Storage & Stability

Ipamorelin is relatively stable among peptides. Standard storage practices will maintain potency throughout a cycle.

Side Effects & Considerations

Ipamorelin has one of the most favorable side effect profiles among GH secretagogues, owing to its selectivity.

Commonly Reported

• Head rush or lightheadedness — occurring immediately after injection, transient, resolving in minutes.
• Water retention — particularly in the first week of use. Usually subsides as the body adjusts.
• Tingling in fingers and toes — carpal tunnel-like symptoms from GH elevation, dose-dependent.
• Increased appetite — milder than GHRP-6 but present in some individuals.
• Mild headache — during initial use, typically resolving with continued use.

Key Safety Features

• Does not significantly elevate cortisol, prolactin, or aldosterone at standard doses — the defining advantage over other GHRPs [1].
• No effect on blood glucose at therapeutic doses (unlike exogenous HGH).
• Fasting is important; food before or immediately after injection reduces efficacy by elevating insulin.
• Cycling is recommended to prevent GHS receptor desensitization.

Stacking Protocols

Ipamorelin is most commonly combined with CJC-1295 (no DAC / Mod GRF 1-29). This is one of the most widely used peptide stacks in the research community.

Ipamorelin + CJC-1295 (GH Optimization Stack)

Ipamorelin (GHS receptor) and CJC-1295 (GHRH receptor) activate different receptor pathways on the same pituitary somatotroph cells. Co-administration produces synergistic GH release — the combined output exceeds the mathematical sum of either peptide administered alone.

Lifestyle Factors

Research suggests the following practices optimize GH-secretagogue protocols:

• Sleep: The pre-sleep dose is the most important. Growth hormone secretion peaks during slow-wave sleep. Prioritize 7–9 hours of uninterrupted sleep.
• Fasting discipline: Maintain at least a 2-hour fast before each injection. Insulin suppresses pituitary GH release directly. This is the single most common reason for suboptimal response.
• Resistance training: Exercise itself stimulates GH release. Timing an ipamorelin injection post-workout (while still fasted or lightly fed) can compound the GH pulse.
• Body composition: Higher body fat levels impair GH secretion in response to GHRP stimulation. Progressive fat loss during the cycle may improve responsiveness.
• Protein intake: Adequate protein (1.2–1.6 g/kg body weight) supports the anabolic effects of elevated GH/IGF-1.

Related Peptides

Researchers studying ipamorelin often investigate these related compounds:

Literature & Citations

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed
2. Gobburu JV, Agersoe H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PubMed
3. Hansen BS, Raun K, Nielsen KK, et al. Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999;141(2):180-189. PubMed
4. Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PubMed
5. Anderson LL, Jeftinija S, Scanes CG. Growth hormone secretion: molecular and cellular mechanisms and in vivo approaches. Exp Biol Med. 2004;229(4):291-302. PubMed
6. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. PubMed